ATE327747T1 - Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses - Google Patents

Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses

Info

Publication number
ATE327747T1
ATE327747T1 AT00121950T AT00121950T ATE327747T1 AT E327747 T1 ATE327747 T1 AT E327747T1 AT 00121950 T AT00121950 T AT 00121950T AT 00121950 T AT00121950 T AT 00121950T AT E327747 T1 ATE327747 T1 AT E327747T1
Authority
AT
Austria
Prior art keywords
lysine
cancer
treatment
ascorbate
arginine
Prior art date
Application number
AT00121950T
Other languages
English (en)
Inventor
Matthias Dr Med Rath
Original Assignee
Matthias Dr Med Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Dr Med Rath filed Critical Matthias Dr Med Rath
Application granted granted Critical
Publication of ATE327747T1 publication Critical patent/ATE327747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT00121950T 2000-10-09 2000-10-09 Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses ATE327747T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00121950A EP1195159B1 (de) 2000-10-09 2000-10-09 Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses

Publications (1)

Publication Number Publication Date
ATE327747T1 true ATE327747T1 (de) 2006-06-15

Family

ID=8170040

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00121950T ATE327747T1 (de) 2000-10-09 2000-10-09 Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses

Country Status (6)

Country Link
EP (1) EP1195159B1 (de)
AT (1) ATE327747T1 (de)
DE (1) DE60028376T2 (de)
DK (1) DK1195159T3 (de)
ES (1) ES2261136T3 (de)
PT (1) PT1195159E (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77660C2 (en) 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
AU2002326756A1 (en) * 2001-08-24 2003-03-10 Vadim Ivanov Ascorbic acid derivatives with amino acids
AU2003235762B2 (en) * 2002-01-11 2008-10-02 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
WO2004108127A1 (en) * 2003-05-30 2004-12-16 Matthias Rath Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
BRPI0520221A2 (pt) * 2005-04-11 2009-04-22 Matthias Rath uso de uma composiÇço nutriente que compreende polifenàis de chÁ verde para tratamento de osteossarcoma
FR2884692B1 (fr) * 2005-04-21 2009-08-14 Formquest Ltd Complement alimentaire comprenant une association d'agents antioxydants et de carnitine, obtenue par synthese endogene ou exogene, comme aide a la fertilite chez l'homme et chez la femme
WO2007016953A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing alcohol induced liver cancer risk
WO2007016952A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer
WO2007016951A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced pancreatic cancer
WO2007016950A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced neurodegenerative disease
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
WO2007016954A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing drug or alcohol induced breast cancer risk
US8580750B2 (en) * 2005-07-29 2013-11-12 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
WO2007016949A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced neuropathy
CA2873179A1 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Use of bryostatins and neristatins in the treatment of cognitive impairment due to head trauma
WO2010011927A1 (en) 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP2595636A4 (de) * 2010-07-22 2014-01-15 Reven Pharmaceuticals Inc Verfahren zur behandlung oder linderung von krankheiten und zur leistungserhöhung durch verwendung einer durch magnetische dipole stabilisierten lösung
AT510810B1 (de) * 2010-12-09 2017-09-15 Gonadosan Gmbh Kombinationspräparat zur verbesserung der weiblichen fertilität
WO2022124386A1 (en) * 2020-12-07 2022-06-16 L' Oreal Composition comprising ascorbic acid and cyclic amino acid
CN113082051B (zh) * 2021-03-29 2022-10-25 北京诺康达医药科技股份有限公司 一种复方维生素和微量元素口服溶液及其制备方法
US11654131B1 (en) * 2022-05-04 2023-05-23 Matthias W. Rath Composition and method of treatment of health issues related to estrogen metabolism with elevated risk factors in females

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
EP0891771A1 (de) * 1997-07-08 1999-01-20 Health Now, Inc. Lysin und Ascorbat oder ihre Derivate zur Behandlung von kardiovaskulären Erkrankungen

Also Published As

Publication number Publication date
EP1195159B1 (de) 2006-05-31
EP1195159A1 (de) 2002-04-10
DE60028376T2 (de) 2007-06-06
ES2261136T3 (es) 2006-11-16
PT1195159E (pt) 2006-08-31
DE60028376D1 (de) 2006-07-06
DK1195159T3 (da) 2006-10-02

Similar Documents

Publication Publication Date Title
DE60028376D1 (de) Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses
HRP20030831B1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE69435086D1 (de) Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
ATE136030T1 (de) Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
CY1111999T1 (el) Λακτοφερρινη στην αγωγη κακοηθων νεοπλασματων και αλλων υπερπλαστικων νοσων
AR027355A1 (es) Acidos tiazolidincarboxilicos
DE69007319T2 (de) Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
SI3449934T1 (sl) Zdravljenje bolezni kopičenja glikogena tip II
DE59100067D1 (de) Orale arzneimittelformen von pimobendan.
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
DK1001775T3 (da) Medikament indeholdende yohimbin og arginin beregnet til behandling af erektil dysfunktion
ATE81004T1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
HUP0203197A2 (hu) Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére
NO924453L (no) Fremgangsmaate for fremstilling av et pasteurisert trombinkonsentrat
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
AU2003292006A1 (en) 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
DE60019937D1 (de) Kombination therapie mit pentafluorobenzenesulfonamid und platin-derivate
EP1038524A4 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1195159

Country of ref document: EP